ClearPoint Neuro (CLPT) stock soared on Friday alongside new filings with the Securities and Exchange Commission (SEC). In these filings, the company revealed new insider buying from three members of the company’s Board of Directors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Let’s see how many shares of ClearPoint Neuro stock these insiders bought.
- Director Timothy Richards purchased 555 shares of CLPT stock for an average price of $21.79 each and now directly owns 78,870 shares.
- Director Pascal Girin bought 315 shares of CLPT stock for an average price of $21.79 each and now directly owns 96,949 shares.
- Director John Fletcher acquired 265 shares of CLPT stock for an average price of $21.79 each and now directly owns 116,240 shares.
ClearPoint Neuro Stock Movement Today
ClearPoint Neuro stock was up 12.97% on Friday, following a 19.8% rally yesterday. The shares have increased 62.87% year-to-date and 123.46% over the past 12 months. Despite today’s rally, trading remained limited at about 150,000 shares, compared to a three-month daily average of 925,000 units.
Investors curious about yesterday’s rally will note an announcement from ClearPoint Neuro earlier this week. The company revealed its proprietary Robotic Neuro-Navigation System that will allow the KUKA LBR Med Robotic Arm to perform minimally invasive cranial surgical procedures.
Is ClearPoint Neuro Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for ClearPoint Neuro is Moderate Buy, based on a single Buy rating over the past three months. With that comes a $30 price target, representing a potential 19.76% upside for the shares.
